Oral News and Research

RSS

Researchers discover genetic links to kidney failure, diabetic kidney disease

Researchers at the Translational Genomics Research Institute will make two presentations at this week's 70th Scientific Sessions of the American Diabetes Association, June 25-29, in Orlando, Florida.

28 Jun 2010

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

OraSure Technologies, Inc. announced today that its OraQuick Hepatitis C Rapid Antibody Test has been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies in venous whole blood specimens, making it the first rapid HCV test approved by the FDA for use in the United States.

28 Jun 2010

Kansas doctor and wife found guilty of prescribing painkillers, causing deaths

"A federal jury Thursday found a Kansas doctor and his wife guilty of conspiring to profit from illegally prescribing painkillers to dozens of patients who later died, in a case highlighting medical treatment of chronic pain sufferers and prescription drug abuse."

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.

25 Jun 2010

Investment report on Somaxon Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

25 Jun 2010

Medicare to use new fraud identification tool

Gov Info Security: "The Centers for Medicare & Medicaid Services is the first agency to use a new fraud mapping tool that ultimately will be used throughout the federal government.

25 Jun 2010

Editors of Canadian Medical Association Journal warn polio outbreak in Tajikistan could spread

"A large polio outbreak in Tajikistan - Europe's first in years - has the potential to further spread the dangerous virus to other regions of the world, the [editors of] the Canadian Medical Association Journal [CMAJ] warned Wednesday" in an editorial appearing in the journal, the Canadian Press reports.

25 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

MonoSol Rx, Midatech collaborate to develop peptides for therapeutic delivery utilizing pharmaceutical films

MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the expansion of its agreement with Midatech Group (Oxford, UK) to develop nanoparticle-based proteins and peptides for therapeutic delivery utilizing pharmaceutical films. Under the terms of the expanded agreement, MonoSol Rx has made an equity investment in Midatech and Keith Kendall, Executive Vice President and Chief Financial Officer of MonoSol Rx, will join the Midatech Board of Directors.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.

24 Jun 2010

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.

24 Jun 2010

UNC team provides first example of successful radiomitigation in mammals

While radiation has therapeutic uses, too much radiation is damaging to cells. The most important acute side effect of radiation poisoning is damage to the bone marrow. The bone marrow produces all the normal blood cells, and therefore a high dose of radiation can lead to low blood counts of red cells, platelets and white blood cells.

24 Jun 2010

AVEO receives EMA orphan medicinal product designation for tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency (EMA).

24 Jun 2010

Risk, incidence of VTE differs between races

A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published today in the American Journal of Hematology.

24 Jun 2010

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

Aphios Corporation today announced that it was awarded United States Patent No. 7,708,915 B2 for "Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein," granted May 04, 2010. This invention is an improved process to formulate polymeric microspheres and nanospheres, and encapsulate therapeutic proteins or other useful substances, and a polymer microspheres/nanospheres apparatus.

24 Jun 2010

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

The Cancer Prevention and Research Institute of Texas has granted $3.7 million to Rice University researchers to fund an innovative cancer diagnostics program.

24 Jun 2010

San Francisco dentist recognized with Presidential Award at SCDA's annual national meeting

Dr. David Blende of San Francisco was recognized for his many years of service to the Special Care Dentistry Association when the organization presented Dr. Blende with their Presidential Award. The Awards Ceremony took place Sunday, March 28, 2010, at the SCDA's annual national meeting at the Swissotel in Chicago.

23 Jun 2010

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Groundbreaking studies will be presented at the ESMO 12th World Congress on Gastrointestinal Cancer next week in Barcelona, Spain, including exciting new data on treatment for neuroendocrine tumors. "The presentations this year are very significant for clinicians, and outline real progress in the development of agents that are effective in managing and treating gastrointestinal diseases," says Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven, Belgium and Congress co-chair.

23 Jun 2010

Oral News and Research

Researchers discover genetic links to kidney failure, diabetic kidney disease

FDA approves OraSure Technologies' OraQuick HCV Rapid Antibody Test

Kansas doctor and wife found guilty of prescribing painkillers, causing deaths

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

Investment report on Somaxon Pharmaceuticals

Medicare to use new fraud identification tool

Editors of Canadian Medical Association Journal warn polio outbreak in Tajikistan could spread

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

MonoSol Rx, Midatech collaborate to develop peptides for therapeutic delivery utilizing pharmaceutical films

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

UNC team provides first example of successful radiomitigation in mammals

AVEO receives EMA orphan medicinal product designation for tivozanib

Risk, incidence of VTE differs between races

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

San Francisco dentist recognized with Presidential Award at SCDA's annual national meeting

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News